Physician profile
Cara Guminik
NPI 1790300275
$1,813.74
in general payments reported to CMS, 2019-2025
23 companies · $327 in 2025
The $327 reported for 2025 was less than what a typical Vascular Neurology provider received nationally (typical 2025 total: $360).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $246 · 2022: $450 · 2023: $624 · 2024: $167 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,117.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $296.40 | 2021-2025 | Nayzilam, Briviact |
| Abbvie INC. | $213.01 | 2021-2023 | Qulipta, Ubrelvy, Duopa |
| Penumbra, INC. | $211.42 | 2022-2023 | Red 72 |
| E.R. Squibb & Sons, L.L.C. | $188.08 | 2021-2023 | Zeposia |
| Depuy Synthes Sales INC. | $120.79 | 2024 | Cerebase |
| Jazz Pharmaceuticals INC. | $101.96 | 2022-2023 | Epidiolex |
| Novo Nordisk INC | $94.09 | 2023 | |
| Route 92 Medical, INC. | $93.48 | 2025 | |
| Medtronic, INC. | $78.58 | 2022 | |
| Neuropace, INC. | $66.70 | 2021 | |
| Allergan, INC. | $59.83 | 2022 | |
| Biogen, INC. | $51.75 | 2025 | Skyclarys, Spinraza |
| Novartis Pharmaceuticals Corporation | $30.14 | 2024 | |
| Lundbeck LLC | $29.00 | 2021 | |
| Tanabe Pharma America, INC. | $27.10 | 2025 | Radicava |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $24.46 | 2025 | Daybue |
| Vanda Pharmaceuticals INC. | $23.81 | 2025 | Ponvory |
| Acorda Therapeutics, INC | $20.88 | 2022 | |
| Sk Life Science, INC. | $17.43 | 2022 | |
| Greenwich Biosciences, INC. | $17.33 | 2021 | |
| Argenx US, INC. | $16.29 | 2023 | Vyvgart |
| Celgene Corporation | $16.16 | 2024 | Zeposia |
| Alexion Pharmaceuticals, INC. | $15.05 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cara Guminik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.